Thorne Quercetin Phytosome
250 mg quercetin phytosome per capsule
Quercetin phytosome capsules.
Best for: comparing a quercetin phytosome option in Key Facts
View on Amazon · Affiliate link
Evidence correction: No human head-to-head trial establishes either flavonoid as a senolytic treatment or longevity aid.
Fisetin and quercetin share a flavonoid backbone and both function as natural senolytics through BCL-2 family inhibition. Fisetin has the stronger preclinical senolytic evidence (Scripps Research 2018), while quercetin has more robust human clinical trial data via the D+Q (dasatinib + quercetin) combination protocol from the Mayo Clinic.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
250 mg quercetin phytosome per capsule
Quercetin phytosome capsules.
Best for: comparing a quercetin phytosome option in Key Facts
View on Amazon · Affiliate link
8 mg fisetin per capsule
Low-dose fisetin with fenugreek galactomannans.
Best for: reviewing a low-dose fisetin label in Key Facts
View on Amazon · Affiliate link
Should I take fisetin or quercetin first?
Start with fisetin if you want the single agent with the strongest preclinical senolytic evidence. Start with quercetin if you prefer alignment with the most human trial data (D+Q protocol). Many practitioners use both in rotation.
Can fisetin and quercetin be taken on the same day?
Yes. Both are flavonoids with complementary mechanisms. Taking them together on burst dosing days is a common and safe approach. No antagonistic interactions have been documented.
Which is better for brain health specifically?
Fisetin has a better documented blood-brain barrier penetration profile and more neuroprotection studies. For cognitive aging specifically, fisetin may be the preferred single agent.
Fisetin and quercetin are plant flavonoids with overlapping laboratory effects, but cell assays cannot rank them for clinical benefit. Differences in absorption, metabolism, dose, and study design make a direct comparison difficult. The widely discussed D+Q regimen includes dasatinib, a prescription medicine; evidence from that combination cannot be attributed to quercetin alone.
Fisetin’s senolytic reputation is based mainly on preclinical work. Human trials remain limited and have not established a routine dose or prevention benefit. Quercetin has been studied in several human settings, but those studies do not prove selective clearance of senescent cells or an effect on lifespan. There is no credible evidence that either compound is superior for healthy aging.
Do not select a supplement based on a lab potency chart or combine both to “cover more pathways.” A higher dose is not necessarily more effective and can increase the chance of interactions. Review the entire label, including other ingredients, and check with a clinician if you take anticoagulants, blood-pressure medicines, immunosuppressants, or cancer treatments. Supplements should not replace standard care or be used to change a prescribed medication.
For research participation, compare the trial population, dose, formulation, primary outcomes, and adverse-event plan. A small early-phase study can inform feasibility, but it cannot settle comparative effectiveness. Be cautious with claims that one flavonoid is a “natural dasatinib.”
FAQ
Which is the stronger human senolytic? Neither has proven senolytic benefit in routine human use.
Can I take fisetin and quercetin together? There is no established evidence-based combination or dose; ask a clinician about interactions.
Read the fisetin safety profile and senolytics clinical-trials guide.
The word “natural” does not mean a flavonoid has the same safety profile as food when consumed as a concentrated extract. Product strength, extract composition, and interactions can vary. A person taking several supplements may not be able to tell which one caused a rash, digestive symptom, or change in a laboratory result. If a clinician agrees that a trial is reasonable, changing one product at a time and recording the dose makes follow-up more interpretable.
For people comparing these ingredients because of a health condition, the right question is whether the specific product has been tested for that condition—not whether it scored higher in an in-vitro senolytic assay. No current evidence establishes that either supplement prevents dementia, cancer, cardiovascular disease, or aging. If you have a diagnosis or take prescription medicines, discuss the plan with the clinician managing that care rather than using a supplement comparison as a treatment decision.
Research: Fisetin preclinical senotherapeutic research; small human D+Q pilot.